Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Shares Up 0.4% - Should You Buy?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF - Get Free Report)'s share price rose 0.4% during trading on Monday . The stock traded as high as $27.00 and last traded at $27.00. Approximately 100 shares changed hands during trading, a decline of 75% from the average daily volume of 400 shares. The stock had previously closed at $26.90.

Analyst Ratings Changes

Separately, Barclays raised Swedish Orphan Biovitrum AB (publ) to a "strong-buy" rating in a report on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Price Performance

The firm has a market capitalization of $10.32 billion, a price-to-earnings ratio of 27.88 and a beta of 0.54. The firm has a fifty day moving average price of $28.63 and a 200 day moving average price of $29.01. The company has a current ratio of 0.91, a quick ratio of 0.62 and a debt-to-equity ratio of 0.31.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.